3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 4
2
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pruritus
1
Prostatic Neoplasms
1
Pain
1
Neuropathy, Painful
1
Neuralgia
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Cold Hypersensitivity
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Docetaxel
33
Prednisone
28
enzalutamide
19
Abiraterone Acetate
13
pembrolizumab
11
gallium 68 PSMA-11
9
Leuprolide
9
Radiotherapy
8
Pluvicto
8
Magnetic Resonance Spectroscopy
8
Nivolumab
7
Estramustine
7
abiraterone
6
Radiotherapy, Intensity-Modulated
6
Goserelin
6
Carboplatin
6
Biopsy
6
olaparib
5
cemiplimab
5
bicalutamide
5
Specimen Handling
5
Paclitaxel
5
Cyclophosphamide
5
temsirolimus
4
orteronel
4
darolutamide
4
cabazitaxel
4
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
4
Sirolimus
4
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms
×
Lidocaine
×
Clear all
NCT06661902
2026-02-17
BURN
University of Washington
Phase 1/2
Completed
350 enrolled